Study of an inhaled anthrax treatment after broad exposure
Part of Infections clinical trials.
This trial studies how safe and potentially helpful ANTHRASIL (AIGIV) is for people who have inhalational anthrax after exposure to a known source. If you have suspected or confirmed inhalational anthrax and were treated with AIGIV, you may be able to join this safety-and-benefit study.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have confirmed or suspected inhalational anthrax
- Your illness is linked to a known broad exposure situation
- You have been treated with AIGIV (ANTHRASIL)
- You can give informed consent (or assent if applicable)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This is an observational study (doctors follow people and record outcomes) for patients with systemic anthrax who received AIGIV from the CDC. It aims to learn how safe AIGIV is and what clinical outcomes patients experience after treatment.
This study looks at how safe and helpful raxibacumab is for people who are sick with inhalational anthrax after being exposed in a large incident. It includes all ages and also includes pregnant and breastfeeding people, focusing on outcomes from standard emergency clinical care.
This study observes people in the U.S. who have been treated with a specific anthrax drug (raxibacumab) from the national emergency supply. It helps doctors learn more about how the drug works in real-world cases of anthrax infection.
This trial tests whether giving a medication called intravenous immunoglobulin (IVIG) can help people with IPF who are hospitalized for a sudden worsening of their lung condition. The treatment aims to reduce inflammation and improve recovery.
This trial tests a single inhaled dose of RJ026 in patients with interstitial lung disease (ILD), including idiopathic pulmonary fibrosis (IPF) or connective tissue disease-related ILD (CTD-ILD). It helps see how the drug moves through the body and if it's safe.
This trial tests if an inhaled antibiotic (amikacin) can treat an infection in the breathing tube (ventilator-associated tracheobronchitis) better than a placebo. You may qualify if you are on a ventilator and have this type of infection.
Hear when a new Inhalational Anthrax trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.